Dados do Trabalho

Título

PEDIATRIC MULTIPLE SCLEROSIS POST COVID: A CASE REPORT

Apresentação do caso

Female adolescent, 15 years old, complains that for 6 months she has felt generalized muscle weakness and that has increased in recent days associated with changes in muscle sensitivity in left dimidium, evolving in 1 week to the right and about 15 days after, culminates with bilaterally lower limb plegia. She denies fever and use of medication for continuous use. Her relevant personal history is: tested positive for SARS-CoV-2 6 months before neurological symptoms.
In the neurological evaluation, the muscular strength of the lower limbs was symmetrical of IV and V in the upper limbs, sensory level close to the thoracoabdominal transition (T9-T10) (with impairment of tactile, pain, vibratory and proprioceptive sensitivity), abolished Aquileus reflex, flaccid paraparesis of lower limbs with exaltation of patellar reflexes.
Patient, in the absence of infectious signs, was hospitalized and conducted to methylprednisolone pulsotherapy associated with Omeprazole and Albendazole.
The patient was initially classified as Clinically Isolated Syndrome (CIS) and the diagnosis of the disease was later closed with the result of the liquoric puncture with oligoclonal bands present and thus, the transition was made to the therapy with Glathyromer Acetate, Gabapentin and Vitamin D.

Discussão

Although the pathophysiological mechanisms of SARS-CoV-2 are not completely elucidated, its neuroinvasive capacity is already known for the emergence of post-infectious neurological complications.
In the case described, the patient had acute neurological symptoms of paresis, plegia and loss of muscle sensitivity about 6 months after infection with COVID-19. As it is a viral infection with complications in multiple systems and, among them, the central nervous system by neurotropism, it is likely that COVID-19 has played a trigger role for the development of MS.
The subsequent liquoric puncture with the presence of oligoclonal bands made it possible to confirm the DM picture by applying the diagnostic criteria of McDonald 2017.

Comentários finais

Although there is little scientific evidence available on this subject, we believe that there is a late stage of multiple sclerosis, probably associated with SARS-CoV-2 infection.
Thus, we expect that the exposure and discussion of this clinical case might collaborate - as a form of evidence -, with the knowledge at the disposal of this pathology in pediatrics.

Referências (se houver)

BRASIL, Ministério da Saúde. Coronavírus - Sintomas. 2021. Disponível em: https://www.gov.br/saude/pt-br/coronavirus/sintomas. Acesso em 15 dez de 2021

BOZIKI, Marina Kleopatra; et. al. COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sci. 2020;10:345. doi: 10.3390/brainsci10060345.

BSTEH, Gabriel; et al. Multiple sclerosis and COVID-19: How many are at risk?. Eur J Neurol. 2020 Sep 25: 10.1111/ene.14555

CHRISTY, Alisson. COVID-19: A Review for the Pediatric Neurologist. Journal of Child Neurology 2020, Vol. 35(13) 934-939

DOBSON, R; GIOVANNO, G. Multiple sclerosis - a review. Eur. J. Neurol. 26, 27–40 (2019). https://doi.org/10.1111/ene.13819.

FEINSTEN, A. Multiple sclerosis and depression. Mult Scler. 2011 Nov;17(11):1276-81. doi: 10.1177/1352458511417835.

FILIPPI, M; et al. Multiple sclerosis. Nat Rev Dis Primers 4, 43 (2018). https://doi.org/10.1038/s41572-018-0041-4.

GITAÍ, D. et al. Neurobiologia e COVID-19 – Maceió, AL: EDUFAL, 2020. 112 p.

LOPES, F.A.; CAMPOS, D. Jr. Tratado de Pediatria. Sociedade Brasileira de Pediatria. 4ª Ed. Barueri, SP: Manole, 2017.
LOTZE, Timothy E. Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis. Curr Neurol Neurosci Rep. http://www.uptodate. com/store. 2004; 4 (3): 245.

MAO, L.; et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-690. doi:10.1001/jamaneurol.2020.1127

MARESA, Jan; HARTUNG, Han Peter. Multiple sclerosis and COVID-19. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep; 164(3):217-225.

MARQUES, T.; et al. Esclerose múltipla e SARS - COV2 (Trigger ou coincidência?): relato de caso. Brazilian Journal of Health Review, Curitiba, v. 5, n. 3,p.9499-9508, may./jun., 2022.

MCGINLEY, M.P.; GOLDSCHMIDT, C.H.; RAE-GRANT, A. Diagnóstico e tratamento da esclerose múltipla: uma revisão. JAMA, 325 8 , 765-779

MONTALVAN, V.; et al. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clinical Neurology and Neurosurgery 194 (2020) 105921

MINISTÉRIO DA SAÚDE. Protocolo clínico e diretrizes terapêuticas da Esclerose Múltipla. Portaria Conjunta nº 7, de 3 de julho de 2019. Disponível em: www.portal.saude.gov.br. Acesso em 19 nov.2021.

NIAKAR, H.R. et al. The neurological manifestations of COVID-19: a review article. Neurol Sci (2020) 41:1667–1671

PAN, Yuehai et al. Role of the SphK‐S1P‐S1PRs pathway in invasion of the nervous system by SARS‐CoV‐2 infection. Clinical and Experimental Pharmacology and Physiology, v. 48, n. 5, p. 637-650, 2021.
SADEGHMOUSAVI, S; REZAEI, N. COVID-19 and Multiple Sclerosis: Predisposition and Precautions in Treatment. SN comprehensive clinical medicine. SN Compr. Clin. Med. 2, 1802–1807 (2020).
SATHEESH, Noothan J.; SALLOUM-ASFAR, Salam; ABDULLA, Sara A. The Potential Role of COVID-19 in the Pathogenesis of Multiple Sclerosis—A Preliminary Report. Viruses 2021, 13, 2091. https://doi.org/10.3390/v13102091.

SAWAR, S.; et al. Multiple Sclerosis Following SARS-CoV-2 Infection: A Case Report and Literature Review

VEAUTHIER, C; SLEEP, P. F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med. 2014;5(1):5-4. doi:10.1016/j.sleep.2013.08.791

WOUK, J.; et al. Viral infections and their relationship to neurological disorders. Arch Virol., v. 166, n. 3, p. 733-753, 2021.

Fonte de Fomento (se houver)

Declaração de conflito de interesses de TODOS os autores

Negamos qualquer conflito de interesse

Área

Neuroimunologia, esclerose múltipla e outras doenças desmielinizantes